Shares of Neuland Laboratories Ltd surged more than 2% on Tuesday, trading at ₹16,041, after the company reported a stellar rise in export performance for August 2025. The pharma firm posted exports worth USD 12 million, marking a massive 433% year-on-year jump and an equally striking 250% month-on-month growth. The strong export momentum has boosted investor sentiment, pushing the stock to one of its recent highs.
Neuland’s rally comes amid robust export data across key pharma companies. Divi’s Laboratories reported exports of USD 89 million for August 2025, up 5% YoY and 32% MoM, underscoring steady global demand for its APIs and custom synthesis products. Similarly, Laurus Labs posted exports worth USD 37.4 million, recording a sharp 94% YoY growth and 6% MoM increase, reflecting continued traction in its formulations and synthesis segments.
The broader sector has seen mixed performances. Blue Jet Healthcare’s exports came in at USD 3.9 million, down from USD 8 million in August 2024 and USD 4.8 million in July 2025. Syngene International also reported weaker exports of USD 7 million compared to USD 12 million last year and USD 8 million in July 2025.
The latest figures highlight a contrasting trend where large players like Divi’s and Laurus continue steady expansion, while mid-cap firms like Neuland have shown extraordinary growth, reinforcing their global competitiveness.
⚠️Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
